Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 14;73(18):2286-2295.
doi: 10.1016/j.jacc.2019.02.046.

Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study

Rabea Asleh  1 , Maurice Enriquez-Sarano  1 , Allan S Jaffe  1 , Sheila M Manemann  2 , Susan A Weston  2 , Ruoxiang Jiang  2 , Véronique L Roger  3
Affiliations

Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study

Rabea Asleh et al. J Am Coll Cardiol. .

Abstract

Background: Galectin-3 (Gal-3) is implicated in cardiac fibrosis, but its association with adverse outcomes after myocardial infarction (MI) is unknown.

Objectives: The purpose of this study was to examine the prognostic value of Gal-3 in a community cohort of incident MI.

Methods: A population-based incidence MI cohort was prospectively assembled in Olmsted County, Minnesota, between 2002 and 2012. Gal-3 levels were measured at the time of MI. Patients were followed for heart failure (HF) and death.

Results: A total of 1,342 patients were enrolled (mean age 67.1 years; 61.3% male; 78.8% non-ST-segment elevation MI). Patients with elevated Gal-3 were older and had more comorbidities. Over a mean follow-up of 5.4 years, 484 patients (36.1%) died and 368 (27.4%) developed HF. After adjustment for age, sex, comorbidities, and troponin, patients with Gal-3 values in tertiles 2 and 3 had a 1.3-fold (95% confidence interval [CI]: 0.9-fold to 1.7-fold) and a 2.4-fold (95% CI: 1.8-fold to 3.2-fold) increased risk of death, respectively (ptrend < 0.001) compared with patients with Gal-3 values in tertile 1. Patients with Gal-3 values in tertiles 2 and 3 had a higher risk of HF with hazard ratios of 1.4 (95% CI: 1.0 to 2.0) and 2.3 (95% CI: 1.6 to 3.2), respectively (ptrend < 0.001). With further adjustment for soluble suppression of tumorigenicity-2, elevated Gal-3 remained associated with increased risk of death and HF. The increased risk of HF did not differ by HF type and was independent of the occurrence of recurrent MI.

Conclusions: Gal-3 is an independent predictor of mortality and HF post-MI. These findings suggest a role for measuring Gal-3 levels for risk stratification post-MI.

Keywords: biomarkers; galectin-3; heart failure; mortality; myocardial infarction; population-based study.

PubMed Disclaimer

Figures

Central Illustration.
Central Illustration.
Cumulative incidence of death (A) and heart failure treating death as a competing risk (B) after incident myocardial infarction according to tertiles of Galectin-3. Number of subjects at risk over follow-up is presented by Galectin-3 tertile. MI indicates myocardial infarction.
See this image and copyright information in PMC

Comment in

  • Should a High Gal-3 Have Us Scared Stiff?
    Daniels LB, Bui QM. Daniels LB, et al. J Am Coll Cardiol. 2019 May 14;73(18):2296-2298. doi: 10.1016/j.jacc.2019.02.047. J Am Coll Cardiol. 2019. PMID: 31072573 No abstract available.

References

    1. Roger VL, Weston SA, Gerber Y, et al. Trends in incidence, severity, and outcome of hospitalized myocardial infarction. Circulation 2010;121:863–9. - PMC - PubMed
    1. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010;362:2155–65. - PubMed
    1. Gerber Y, Weston SA, Jiang R, Roger VL. The changing epidemiology of myocardial infarction in Olmsted County, Minnesota, 1995–2012. Am J Med 2015;128:144–51. - PMC - PubMed
    1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation 2017;135:e146–e603. - PMC - PubMed
    1. Cohn J, Ferrari R, Sharpe N. Cardiac remodeling- Concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. Journal of the American College of Cardiology 2000;35:569–582. - PubMed

Publication types

MeSH terms